Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biomed Pharmacother. 2013 Apr;67(3):192-6. doi: 10.1016/j.biopha.2012.11.009. Epub 2012 Dec 28.

A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.

Author information

  • 1Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, SP, Brazil.

Abstract

Cancer is linked to hypercoagulability, and many studies have shown that anticoagulant drugs affect tumor progression. In this study was demonstrated that the Amblyomin-X (which is a recombinant protein that exerts similarity to the Kunitz-type inhibitors and shows pro-apoptotic effects in different tumor cell lines) and heparin (a classic anticoagulant) have similar effects on cancer progression and on normalization of the hypercoagulable state. However, Amblyomin-X showed a distinct mechanism in triggering its effects in vitro, because it exerted a cytotoxic effect in cancer cells by inducing apoptosis and promoting cell cycle arrest.

Copyright © 2013 Elsevier Masson SAS. All rights reserved.

PMID:
23433900
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk